Triple combination of antibiotics could be the new arsenal against drug-resistant bacteria

FHS
June 4, 2024
5:59 pm

In the ongoing battle against antibiotic resistance, a new study published in Engineering by Zhuoren Ling’s research team unveils a promising triple combination of antibiotics that significantly expands our arsenal against drug-resistant bacteria.

Coeptis licenses Deverra Therapeutics’ clinical stage assets

DVX201 is being assessed in a Phase I clinical study for treating haematologic malignancies and viral infections. Credit: Kateryna Kon/Shutterstock.com. Coeptis Therapeutics has exclusively licensed

August 18, 2023

FDA approves Duchenne gene therapy with hefty $3.2m price tag – Pharmaceutical Technology

The approval comes after an intermittent regulatory home stretch for Sarepta’s Duchenne therapy. Image credit: Shutterstock/T. Schneider. Children with a confirmed mutation of the DMD

June 23, 2023

New mobile app aids in rehabilitating hemiparesis following stroke

Brazilian researchers have developed a cell phone application that helps rehabilitate people who have suffered a stroke.

March 12, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.